Advertisement

Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis

Published:October 17, 2016DOI:https://doi.org/10.1016/j.euf.2016.02.001

      Abstract

      Context

      Phosphodiesterase type 5 inhibitors (PDE5-Is) are prescribed off-label for the treatment of premature ejaculation (PE).

      Objective

      To systematically review the evidence from randomised controlled trials (RCTs) for PDE5-Is in the management of PE.

      Evidence acquisition

      Medline and other databases were searched through September 2015. Quality of RCTs was assessed. Intravaginal ejaculatory latency time (IELT) data were pooled in a meta-analysis. Heterogeneity was assessed.

      Evidence synthesis

      Fifteen RCTs were included. The majority were of unclear methodological quality. Pooled IELT evidence suggests that PDE5-Is are significantly more effective than placebo (231 participants, p < 0.00001), that there is no difference between PDE5-Is and selective serotonin reuptake inhibitors (SSRIs; 405 participants, p = 0.50), and that PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone (521 participants, p = 0.001); however, high levels of statistical heterogeneity are evident (I2 ≥ 40%). Single-RCT evidence suggests that sildenafil is significantly more effective than the squeeze technique, but both lidocaine gel and tramadol are significantly more effective than sildenafil. Sildenafil combined with behavioural therapy is significantly more effective than behavioural therapy alone. Sexual satisfaction and ejaculatory control appear to be better with PDE5-Is compared with placebo and with PDE5-Is combined with an SSRI compared with an SSRI alone. Adverse events are reported with both PDE5-Is and other agents.

      Conclusions

      PDE5-Is are significantly more effective than placebo and PDE5-Is combined with an SSRI are significantly more effective than SSRIs alone at increasing IELT and improving other effectiveness outcomes; however, heterogeneity is evident across RCTs. The methodological quality of the majority of RCTs is unclear.

      Patient summary

      We reviewed phosphodiesterase type 5 inhibitors (PDE5-Is) for treating premature ejaculation. We found evidence to suggest that PDE5-Is are effective compared with placebo and that PDE5-Is combined with an SSRI are more effective than an SSRI alone. Adverse events are reported with PDE5-Is and other agents; however, the quality of the evidence is uncertain.

      Trial registration

      PROSPERO registration number CRD42013005289

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Urology Focus
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McMahon C.G.
        • Althof S.
        • Waldinger M.D.
        • et al.
        An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation.
        BJU Int. 2008; 102: 338-350
        • Godpodinoff M.L.
        Premature ejaculation: clinical subgroups and etiology.
        J Sex Marital Ther. 1989; 15: 130-134
        • Serefoglu E.C.
        • McMahon C.G.
        • Waldinger M.D.
        • et al.
        An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine ad hoc committee for the definition of premature ejaculation.
        Sex Med. 2014; 2: 41-59
        • Richardson D.
        • Goldmeier D.
        • Green J.
        • Lamba H.
        • Harris J.R.W.
        Recommendations for the management of premature ejaculation: BASHH Special Interest Group for Sexual Dysfunction.
        Int J STD AIDS. 2006; 17: 1-6
        • Asimakopoulos A.D.
        • Miano R.
        • Finazzi Agro E.
        • Vespasiani G.
        • Spera E.
        Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis.
        J Sex Med. 2012; 9: 2404-2416
        • Aversa A.
        • Francomano D.
        • Bruzziches R.
        • Natali M.
        • Spera G.
        • Lenzi A.
        Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?.
        Int J Impot Res. 2011; 23: 17-23
        • Burton T.D.
        • Liday C.
        The comparison of combination SSRI and PDE-5 inhibitor therapy to SSRI monotherapy in men with premature ejaculation.
        Ann Pharmacother. 2011; 45: 1000-1004
        • Chen J.
        • Keren-Paz G.
        • Bar-Yosef Y.
        • Matzkin H.
        The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.
        Eur Urol. 2007; 52: 1331-1339
        • McMahon C.G.
        • McMahon C.N.
        • Leow L.J.
        • Winestock C.G.
        Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
        BJU Int. 2006; 98: 259-272
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6: e1000097
        • Cooper K.
        • Martyn-St James M.
        • Kaltenthaler E.
        • Dickinson K.
        • Cantrell A.
        Interventions to treat premature ejaculation: a systematic review short report.
        Health Technol Assess. 2015; 19: 1-180
      1. Higgins JPT, Altman DG, Sterne JAC. Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Assessing risk of bias in included studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011]. Cochrane Collaboration Web site. http://handbook.cochrane.org. Accessed 4 January 2016.

      2. Review Manager (RevMan) [computer program]. Version 5.2. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.

        • Culha M.
        • Ozkan L.
        • Ozkurkcugil C.
        • Gokalp A.
        Comparison of fluoxetine vs. fluoxetine plus tadalafil in the treatment of premature ejaculation - a double blind, placebo control study.
        J Sex Med. 2008; 5: 60-61
        • Mathers M.J.
        • Klotz T.
        • Roth S.
        • Lummen G.
        • Sommer F.
        Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study.
        Andrologia. 2009; 41: 169-175
        • Wang W.F.
        • Wang Y.
        • Minhas S.
        • Ralph D.J.
        Can sildenafil treat primary premature ejaculation? A prospective clinical study.
        Int J Urol. 2007; 14: 331-335
        • Zhang X.
        • Tang D.
        • Yang J.
        • et al.
        Combination of sertraline and sildenafil versus sertraline monotherapy in the treatment of acquired premature ejaculation without concomitant diseases.
        Andrology. 2014; 3: 117
        • Tang W.
        • Ma L.
        • Zhao L.
        • Liu Y.
        Efficacy and safety of sertraline, viagra and cardura in patients with premature ejaculation.
        Chin J Androl. 2004; 18 (25): 20-22
        • Zhang X.S.
        • Wang Y.X.
        • Huang X.Y.
        • Leng J.
        • Li Z.
        • Han Y.F.
        Comparison between sildenafil plus sertraline and sertraline alone in the treatment of premature ejaculation.
        Zhonghua Nan Ke Xue. 2005; 11: 520-525
        • Lee W.K.
        • Cho S.T.
        • Lee Y.S.
        • et al.
        Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with premature ejaculation; prospective, randomized, doubleblind, and placebo-controlled.
        J Sex Med. 2012; 9: 203-204
        • Atan A.
        • Basar M.M.
        • Tuncel A.
        • Ferhat M.
        • Agras K.
        • Tekdogan U.
        Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation.
        Urology. 2006; 67: 388-391
        • Mattos R.M.
        • Marmo Lucon A.
        • Srougi M.
        Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.
        Urol Int. 2008; 80: 162-165
        • McMahon C.G.
        • Stuckey B.G.A.
        • Andersen M.
        • et al.
        Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation.
        J Sex Med. 2005; 2: 368-375
        • Gameel T.A.
        • Tawfik A.M.
        • Abou-Farha M.O.
        • Bastawisy M.G.
        • El-Bendary M.A.
        • El-Gamasy Ael-N.
        On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial.
        Arab J Urol. 2013; 11: 392-397
        • Hosseini M.M.
        • Yarmohammadi H.
        Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation.
        Urol Int. 2007; 79: 28-32
        • Mokhtari G.
        • Damavand R.S.
        • Khosropanah I.
        • et al.
        The efficacy and safety of combination therapy with tadalafil and serteraline in lifelong premature ejaculation: a randomized double blind study using a validated questionnaire.
        Int J Urol. 2014; 21: A274
        • Polat E.C.
        • Ozbek E.
        • Otunctemur A.
        • Ozcan L.
        • Simsek A.
        Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation.
        Andrologia. 2015; 47: 487-492
        • Aversa A.
        • Pili M.
        • Francomano D.
        • et al.
        Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation.
        Int J Impot Res. 2009; 21: 221-227
      3. Questions and answers on Priligy (dapoxetine, 30 mg and 60 mg tablets). European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Priligy_29/WC500116880.pdf. Dated 20 January 2012.

        • Hiemke C.
        • Härtter S.
        Pharmacokinetics of selective serotonin reuptake inhibitors.
        Pharmacol Ther. 2000; 85: 11-28
        • van Harten J.
        Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
        Clin Pharmacokinet. 1993; 24: 203-220
        • Hatzimouratidis K.
        • Eardley I.
        • Giuliano F.
        • Moncada I.
        • Salonia A.
        Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.
        European Association of Urology, Arnhem, Netherlands2015
        • Salonia A.
        • Maga T.
        • Colombo R.
        • et al.
        A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation.
        J Urol. 2002; 168: 2486-2489
        • Patrick D.L.
        • Rowland D.
        • Rothman M.
        Interrelationships among measures of premature ejaculation: the central role of perceived control.
        J Sex Med. 2007; 4: 780-788
        • Schulz K.F.
        • Altman D.G.
        • Moher D.
        CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.
        BMJ. 2010; 340: c322
        • Jannini E.A.
        • McMahon C.
        • Chen J.
        • Aversa A.
        • Perelman M.
        The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.
        J Sex Med. 2011; 8: 2135-2143
      4. Deeks JJ, Higgins JPT, Altman DG. Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011]. Cochrane Collaboration Web site. http://handbook.cochrane.org. Accessed 4 January 2016.

        • Waldinger M.D.
        • Zwinderman A.H.
        • Olivier B.
        • Schweitzer D.H.
        Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
        J Sex Med. 2008; 5: 492-499
        • McMahon C.G.
        Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies–part II–study design, outcome measures, data analysis, and reporting.
        J Sex Med. 2008; 5: 1817-1833